GT Biopharma, Inc.
GTBP
$2.35
$0.062.62%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.21% | 30.66% | 39.06% | 14.84% | -38.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.78% | 15.44% | 7.87% | -15.66% | -45.17% |
| Operating Income | -18.78% | -15.44% | -7.87% | 15.66% | 45.17% |
| Income Before Tax | -27.45% | -41.18% | -86.24% | -898.24% | 46.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.45% | -41.18% | -86.24% | -898.24% | 46.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.45% | -41.18% | -86.24% | -898.24% | 46.96% |
| EBIT | -18.78% | -15.44% | -7.87% | 15.66% | 45.17% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 22.02% | 13.61% | -45.68% | -683.06% | 58.65% |
| Normalized Basic EPS | 22.18% | 13.73% | -44.05% | -125.05% | 58.75% |
| EPS Diluted | 22.02% | 13.61% | -45.68% | -683.06% | 59.18% |
| Normalized Diluted EPS | 22.18% | 13.73% | -44.05% | -125.05% | 58.75% |
| Average Basic Shares Outstanding | 63.44% | 63.42% | 27.85% | 27.49% | 28.29% |
| Average Diluted Shares Outstanding | 63.44% | 63.42% | 27.85% | 27.49% | 28.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |